Cargando…
Dual Inhibition of CDK4/Rb and PI3K/AKT/mTOR Pathways by ON123300 Induces Synthetic Lethality in Mantle Cell Lymphomas
This study describes the characterization of a novel kinase inhibitor, ON123300, which inhibits CDK4/6 and PI3K-δ and exhibits potent activity against mantle cell lymphomas (MCLs) both in vitro and in vivo. We examined the effects of PD0332991 and ON 123300 on cell cycle progression, modulation of t...
Autores principales: | Divakar, Saikrishna A., Reddy, M.V. Ramana, Cosenza, Stephen C., Baker, Stacey J., Perumal, Deepak, Antonelli, Anthony C., Brody, Joshua, Akula, Balaiah, Parekh, Samir, Reddy, E. Premkumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703501/ https://www.ncbi.nlm.nih.gov/pubmed/26174628 http://dx.doi.org/10.1038/leu.2015.185 |
Ejemplares similares
-
Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia
por: Padgaonkar, Amol, et al.
Publicado: (2018) -
Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia
por: Baker, Stacey J., et al.
Publicado: (2019) -
Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent
Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase
5 (ARK5)
por: Reddy, M. V. Ramana, et al.
Publicado: (2014) -
CDK4: a master regulator of the cell cycle and its role in cancer
por: Baker, Stacey J., et al.
Publicado: (2022) -
ON01210.Na (Ex-RAD(®)) Mitigates Radiation Damage through Activation of the AKT Pathway
por: Kang, Anthony D., et al.
Publicado: (2013)